TABLE 3.
Trial design and results of the in vivo efficacy studies
| Study model | Compound | Treatment period (days) postinfection | Dose (mg/kg b.i.d.a) | No. of mice cured/no. infected | MSDb | MRDc |
|---|---|---|---|---|---|---|
| Stringent | Control | 0/4 | 9 | |||
| GHQ168 | 3–6 | 3.5 | 0/4d | 17 | 14 | |
| GHQ242 | 3–6 | 22.9 | 0/4 | 14 | 10 | |
| GHQ243 | 3–6 | 21.7 | 0/4 | 12 | 11 | |
| Early treatment | Control | 0/4 | 7 | |||
| GHQ168 | 1–4 | 3.5 | 3/6e | >32 | >32 |
a
b.i.d., twice a day.
b
MSD, mean survival duration (days postinfection).
c
MRD, mean relapse duration (days), where relapse is defined as the presence of parasites in blood.
d
One mouse died during the treatment but did not have parasites in its blood. Data for mice that died during the treatment but without parasites were excluded from the calculation of MSD and MRD, as the cause of death was unrelated to parasitemia.
e
Three mice died during and after the treatment but did not have parasites in their blood. Data for mice that died during the treatment but without parasites were excluded from the calculation of MSD and MRD, as the cause of death was unrelated to parasitemia.